A Finnish population study shows that signs related to Alzheimer's disease may already be found in the brain in middle age.

Illimis Therapeutics’ Series B round was led by Korean venture capital firm DSC Investment. Seoul-based Illimis Therapeutics has raised 58 billion won ($42 million) to fund its research into ...

A medical breakthrough could soon change how we diagnose one of the most devastating brain diseases of our time. On Bloom, I ...

Previous studies have concluded that early intervention in dementia cases can increase patients' treatment options and ...

Approval was based on results from the Phase IIIb TRAILBLAZER-ALZ 6 trial, which showed that Kisunla achieved comparable ...

A Finnish population study shows that signs related to Alzheimer's disease may already be found in the brain in middle age.

Living with Alzheimer’s disease can be both challenging and frightening. However, stories of resilience and hope can inspire ...

SCIENTISTS have spent decades trying to understand what causes dementia. Is it alcohol? Obesity? Or are some of us simply ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the drug discovery research ...

Acumen and JCR aim to develop a product leveraging Acumen's amyloid beta oligomer-selective antibody expertise and JCR's transferrin-receptor-targeting blood-brain barrier-penetrating technologyPrecli ...

Doctors are regularly overlooking a common hormone-driven cause of high blood pressure -- primary aldosteronism -- ...

Alzheimer’s and brain health deserve attention year-round, as millions are affected by dementia and related conditions.